CN

CN

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech

MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink’s TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.

2024-05-27Learn more

MediLink announces the first patient dosed with YL211

SUZHOU, CHINA, May 2, 2024 -- MediLink Therapeutics (“MediLink”) today announced that the first patient has been successfully dosed with YL211 in a phase I study in the US. MediLink and Roche had previously entered into a worldwide collaboration and license agreement on YL211. Following the execution of this agreement, the Investigational New Drug (IND) application for YL211 has been cleared by the U.S. Food and Drug Administration (FDA), and a phase I study to assess the safety, pharmacokinetics and preliminary efficacy of YL211 in patients with advanced solid tumors has been initiated subsequently.

2024-05-02Learn more

MediLink Therapeutics presents its platform and pipeline progress at AACR 2024

MediLink Therapeutics will present its next-generation TMALIN ("Tumor Microenvironment Activable LINker-payload”) platform and preclinical results of YL205, a novel antibody drug conjugate targeting NaPi2b, at the American Association for Cancer Research 2024 meeting (AACR 2024), which takes place April 5-10 in San Diego, United States. Presented studies are as follows:

2024-04-07Learn more

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology

SUZHOU, CHINA, January 2nd, 2024 -- MediLink Therapeutics (“MediLink”), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.

2024-01-02Learn more

MediLinks Appoints Jason (Jia) Li as Chief Financial Officer

January 1st, 2024, MediLink Therapeutics solemnly announced the official appointment of Mr. Jason (Jia) Li as the company's chief financial officer (CFO). Mr. Li will report to Dr. Tongtong (Tony) Xue, Chairman and CEO of the company, and will be responsible for the overall financial planning and management, corporate finance and IPO, development strategy and other financial work, so as to promote the internationalization process and further steady development of the company's business, and address more unmet clinical needs.

2024-01-01Learn more

MediLink Therapeutics Announces Latest Business Progress with Nona Biosciences

SUZHOU, CHINA, December 15th , 2023 -- MediLink Therapeutics (“MediLink”), today announced that it has entered into a supplemental agreement to the license agreement with Nona Biosciences (“Nona”, a wholly-owned subsidiary of HBM Holdings) in which Nona is entitled to license the ADC product HBM9033 (YL215) jointly developed by the two parties to a licensed independent third party., Pfizer Inc.. (“Pfizer”). MediLink has the right to receive a certain percentage of sub-licensing payment based on the collaboration between Nona and Pfizer.

2023-12-15Learn more

MediLink Therapeutics Welcomes Steve Chin, M.D., As Chief Medical Officer (CMO)

On Oct. 23rd, 2023, MediLink Therapeutics is pleased to announce the appointment of Dr. Steve Chin as Chief Medical Officer (CMO). Dr. Chin will be responsible for MediLink’s clinical trial execution, product registration and optimization of clinical capability in both China and the US.

2023-10-23Learn more

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech

MediLink Therapeutics (“MediLink”), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, on the development of a next-generation antibody-drug conjugate candidate (“ADC”), against Human Epidermal Growth Factor Receptor 3 (HER3).

2023-10-12Learn more
1 2 3 4 5